Curebound Catalyst & Equity grant winners announced. Read the San Diego Business Journal's featured coverage here.
Novel Approaches and New Therapeutic Platforms
Faith Barnett, MD, PhD
Andre Basbaum
Annually, approximately 250,000 people worldwide succumb to glioblastoma (GBM), with a median survival time of just 15 months post-diagnosis, despite treatment. The disease’s complexity leads to near-inevitable recurrence and a dismal 5-year survival rate of 5-7%. Moreover, GBM progressively impairs neurological functions, severely affecting quality of life. Resolute Science is advancing RS-5 and RS-8, two first-in-class therapeutics that leverage our Macrophage-Targeted- Conjugates (MAC-TACs) delivery platform. The most promising candidate will be selected for clinical trials targeting glioblastoma. We anticipate that successful validation of either RS-5 or RS-8 could introduce a groundbreaking treatment option for GBM, offering a safer, and more effective therapeutic to patients who are currently without options.
“Resolute Science’s goal is to provide cancer cures for more people. We are extremely grateful for Curebound’s support & funding, which will allow us to accelerate our preclinical research into brain tumors and GBM specifically.” – Faith Barnett, MD, PhD